The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study.

ABSTRACT:

Background

Dupilumab is an antibody against interleukin-4 receptor α, used in the treatment of atopic dermatitis (AD).

Objectives

To evaluate the efficacy and safety of dupilumab in adult Chinese patients with moderate-to-severe AD.

Methods

In this randomized, double-blind, placebo-controlled, parallel-group, phase III study, conducted between December 2018 and February 2020, patients with AD received dupilumab (300 mg) or placebo once every 2 weeks for 16 weeks, and were followed up for 12 weeks. The primary efficacy endpoint was the proportion of patients with both an Investigator's Global Assessment score of 0-1 and a reduction from baseline of ≥ 2 points at week 16.

Results

Overall, 165 patients (mean age 30·6 years; 71·5% male patients) were randomized; 82

SUBMITTER: Zhao Y 

PROVIDER: S-EPMC9298048 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature